On 9 October 2024, Nanjing Leads Biolabs announced that China’s Center for Drug Evaluation of National Medical Products Administration granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody, for the treatment of patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) who have progressed after receiving two or more lines of chemotherapy.
According to Nanjing Leads Biolabs, clinical data shows that LBL-024 monotherapy has more than doubled both the Objective Response Rate and Overall Survival compared to existing treatments for this disease.